Prakiraan pendapatan perusahaan Krystal Biotech Inc (KRYS)

KRYS (krystalbio.com) - tandha merek perusahaan

Krish Krishnan's team at Krystal Biotech, Inc. (KRYS) has confirmed its R&D potential by releasing an innovative topical gene therapy. The firm's future sales trend demonstrates growth, and the indicator has reached the level of 0.57. Revenues are based on insurance reimbursements for the treatment of rare skin pathologies. Meanwhile, Krystal Biotech, Inc. (KRYS) maintains absolute pricing power thanks to its unique patented HSV-1 vector.

Krystal Biotech, Inc. - Volume dodolan sing dikarepake perusahaan KRYS (periode 04.07.2022 - 17.11.2026)

Rincian metrik komprehensif lan analitis Krystal Corp (KRYS)

- nilai saham lan prakiraan konsensus rega:
Analisis komprehensif perusahaan:KRYS Krystal Biotech
Sampel barang Krystal Biotech Inc

Given the commercialization risks of gene therapy at Krystal Biotech, Inc. (KRYS), the organization's future sales valuation on the GURU.Markets platform serves as a leading indicator of market expectations. Unlike retrospective reporting, this metric synthesizes projected revenue streams, allowing investors to rebalance portfolios in a timely manner to minimize losses from regulatory hurdles or lock in profits at the peak of market optimism.